MA26510A1 - Compositions pharmaceutiques comprenant un sensibilisant a l'insuline et un agent antihyperglycemique pour une methode de traitement du diabete - Google Patents

Compositions pharmaceutiques comprenant un sensibilisant a l'insuline et un agent antihyperglycemique pour une methode de traitement du diabete

Info

Publication number
MA26510A1
MA26510A1 MA25121A MA25121A MA26510A1 MA 26510 A1 MA26510 A1 MA 26510A1 MA 25121 A MA25121 A MA 25121A MA 25121 A MA25121 A MA 25121A MA 26510 A1 MA26510 A1 MA 26510A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
treating diabetes
insulin sensitizer
antihyperglycemic agent
antihyperglycemic
Prior art date
Application number
MA25121A
Other languages
English (en)
Inventor
Dr Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA26510A1 publication Critical patent/MA26510A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fodder In General (AREA)
MA25121A 1997-06-18 1998-06-17 Compositions pharmaceutiques comprenant un sensibilisant a l'insuline et un agent antihyperglycemique pour une methode de traitement du diabete MA26510A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
MA26510A1 true MA26510A1 (fr) 2004-12-20

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25121A MA26510A1 (fr) 1997-06-18 1998-06-17 Compositions pharmaceutiques comprenant un sensibilisant a l'insuline et un agent antihyperglycemique pour une methode de traitement du diabete

Country Status (24)

Country Link
EP (1) EP0975343A1 (fr)
JP (1) JP2001523271A (fr)
KR (1) KR20010013845A (fr)
CN (1) CN1274282A (fr)
AP (1) AP9901720A0 (fr)
AR (2) AR014881A1 (fr)
AU (1) AU8799998A (fr)
BG (1) BG103966A (fr)
BR (1) BR9810186A (fr)
CA (1) CA2294134A1 (fr)
CO (1) CO4940453A1 (fr)
DZ (1) DZ2519A1 (fr)
EA (1) EA200000040A1 (fr)
IL (1) IL133138A0 (fr)
MA (1) MA26510A1 (fr)
NO (1) NO996270L (fr)
NZ (1) NZ501345A (fr)
OA (1) OA11631A (fr)
PE (1) PE89199A1 (fr)
PL (1) PL337577A1 (fr)
SK (1) SK179499A3 (fr)
TR (1) TR199903072T2 (fr)
UY (1) UY25051A1 (fr)
WO (1) WO1998057635A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
HRP20010773B1 (en) 1999-04-23 2005-06-30 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
US20030045553A1 (en) 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
CN101121004B (zh) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 含有胰岛素增敏剂和米格列醇的药物组合物
CN101584705B (zh) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物
CN101584688B (zh) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
JP2001523271A (ja) 2001-11-20
WO1998057635A1 (fr) 1998-12-23
UY25051A1 (es) 2000-09-29
KR20010013845A (ko) 2001-02-26
NO996270D0 (no) 1999-12-17
SK179499A3 (en) 2000-11-07
CO4940453A1 (es) 2000-07-24
AR014881A1 (es) 2001-04-11
PL337577A1 (en) 2000-08-28
OA11631A (en) 2004-11-22
EA200000040A1 (ru) 2000-08-28
IL133138A0 (en) 2001-03-19
CA2294134A1 (fr) 1998-12-23
PE89199A1 (es) 1999-10-23
NZ501345A (en) 2001-10-26
EP0975343A1 (fr) 2000-02-02
BR9810186A (pt) 2000-08-08
TR199903072T2 (xx) 2000-07-21
AR013352A1 (es) 2000-12-27
AU8799998A (en) 1999-01-04
BG103966A (bg) 2000-07-31
AP9901720A0 (en) 1999-12-31
DZ2519A1 (fr) 2003-02-01
NO996270L (no) 1999-12-17
CN1274282A (zh) 2000-11-22

Similar Documents

Publication Publication Date Title
FR09C0055I2 (fr) Composition pharmaceutique comprenant de pioglitazone et du glimepiride pour utilisation dans le traitement du diabete
DZ2520A1 (fr) Composition pharmaceutique pour une méthode de traitement du diabète sucré.
DZ2539A1 (fr) Compositions pharmaceutiques pour le traitement dela résistance à l'insuline.
MX9802130A (es) Agonistas adrenergicos beta3 selectivos.
BE881680A (fr) Composition pharmaceutique a base d'acylcarnitine pour le traitement d'un metabolisme cerebral altere et methode utilisee a cet effet
NO973489D0 (no) Stabilisert gassemulsjon inneholdende fosfolipid til kontrastforbedring ved ultralydundersökelser
DZ2675A1 (fr) Association pharmaceutique pour le traitement d'undysfunctionnement sexuel et compositions la conte nant.
RU2003132054A (ru) Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
DZ2519A1 (fr) Compositions pharmaceutiques comprenant un sensibilisant à l'insuline et un agent antihyperglycémique pour une méthode de traitement du diabéte.
ATE228360T1 (de) Stabilisierte schilddrüsenhormonhaltige arzneimittel
DE69629413D1 (de) Flüssigkristallverbindung und diese enthaltende Flüssigkristall-Zusammensetzung
DZ2521A1 (fr) Compositions pharmaceutiques comprenant de la 5-Ä4-Ä2-(méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜ-thiazolidine-2,4-dione et de l'insuline pour une méthode de traitement.
FI935617A7 (fi) 3,5-substituoituja aminobentsoyyliguanidiineja, menetelmä niiden valmistamiseksi, niiden käyttö lääkkeinä tai diagnostisina aineina sekä niitä sisältävä lääke
FI972669L (fi) Peptidin p277 analogeja ja niitä sisältäviä farmaseuttisia koostumuksia diabeteksen hoitamiseksi ja diagnosoimiseksi
BR0011928A (pt) Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética
MA24571A1 (fr) Compositions comprenant un sensibilisant a l'insuline et un secretagogue d'insuline pour une methode de traitement
FR2513126B1 (fr) Formulations pharmaceutiques comprenant de l'insuline humaine et du c-peptide humain
MA26522A1 (fr) Composition pharmaceutique pour le traitement du diabete sucre et d'etats associes.
FR2752422B1 (fr) Composition pharmaceutique contenant des acides 4-oxo-butanoiques
BR9810292A (pt) Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase
DE69632697D1 (de) Naphtholverbindung sowie Flüssigkristallzusammensetzung und Flüssigkristallelement, die diese Verbindung enthalten
BG102222A (en) The use of derivatives of the sulphaminic acid, acylsulphanomides or sulphamoylcarbamates for the preparation of a medicament for reducing lipoprotein levels
FR2718024B1 (fr) Médicament et composition pharmaceutique pour le traitement de l'inflammation.
FR2834214B1 (fr) Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete